Lubiprostone, a chloride channel activator, has emerged as a significant therapeutic agent in the treatment of chronic idiopathic constipation (CIC), irritable bowel syndrome with constipation (IBS-C), and opioid-induced constipation (OIC). Its effectiveness in enhancing intestinal fluid secretion and improving bowel movement frequency has positioned it as a vital player in the global...
English
Arabic
Français
Español
Português
Deutsch
Dutch
Italiano
Russian
Romaian